Clinical utility of intravitreal fluocinolone acetonide (Iluvien^®) implant in the management of patients with chronic diabetic macular edema: a review of the current literature

References

• CampochiaroPABrownDMPearsonAFAME Study GroupSustained delivery fluocinolone acetonide vitreous inserts provide benefit for at least 3 years in patients with diabetic macular edemaOphthalmology2012119102125213222727177
   PubMed Web of Science ®Google Scholar
• CampochiaroPABrownDMPearsonAFAME Study GroupLong-term benefit of sustained-delivery fluocinolone acetonide vitreous inserts for diabetic macular edemaOphthalmology20111184626635.e221459216
   PubMed Web of Science ®Google Scholar
• AielloLPBeckRWBresslerNMDiabetic Retinopathy Clinical Research Network; Writing Committee. Rationale for the diabetic retinopathy clinical research network treatment protocol for center-involved diabetic macular edemaOphthalmology201111812e5e1422136692
   PubMed Web of Science ®Google Scholar
• BandelloFCunha-VazJChongNVNew approaches for the treatment of diabetic macular oedema: recommendations by an expert panelEye (Lond)201226448549322241014
   PubMed Web of Science ®Google Scholar
• MitchellPWongTYDiabetic Macular Edema Treatment Guideline Working GroupManagement paradigms for diabetic macular edemaAm J Ophthalmol20141573505513e1e824269850
   PubMed Web of Science ®Google Scholar
• MitchellPBandelloFSchmidt-ErfurthUThe RESTORE study: ranibizumab monotherapy or combined with laser versus laser monotherapy for DMEOphthalmology2011118461562521459215
   PubMed Web of Science ®Google Scholar
• DoDVNguyenQDBoyerDda Vinci Study GroupOne-year outcomes of the dA Vinci Study of VEGF Trap-Eye in eyes with diabetic macular edemaOphthalmology201211981658166522537617
   PubMed Web of Science ®Google Scholar
• KuppermannKILUVIEN: area Under the Curve (AUC) Pharmacoki-netics – The CONSTANT Analysis: AUC comparisons to Protocol I Ranibizumab, Deferred Laser and OZURDEXpresented at: ISOPT ClinicalDecember 1; 2016Rome Available from: http://www.isopt-clinical.com/Events/Display/ISOPT2016?Page=ProgramAccessed November 15, 2016
   Google Scholar
• ElmenMJAyalaABresslerNMDiabetic Retinopathy Clinical Research NetworkIntravitreal ranibizumab for diabetic macular edema with prompt versus deferred laser treatment: 5-year randomized trial resultsOphthalmology2012119112312231822999634
   PubMed Web of Science ®Google Scholar
• RajendramRFraser-BellSKainesAA 2-year prospective randomized controlled trial of intravitreal bevacizumab or laser therapy (BOLT) in the management of diabetic macular edema: 24-month data: report 3Arch Ophthalmol2012130897297922491395
   PubMed Web of Science ®Google Scholar
• Diabetic Retinopathy Clinical Research NetworkElmanMJQinHAielloLPIntravitreal ranibizumab for diabetic macular edema with prompt versus deferred laser treatment: three-year randomized trial resultsOphthalmology2012119112312231822999634
   PubMed Web of Science ®Google Scholar
• BresslerSBAyalaARBresslerNMDiabetic Retinopathy Clinical Research NetworkPersistent macular thickening after ranibizumab treatment for diabetic macular edema with vision impairmentJAMA Ophthalmol2016134327828526746868
   PubMed Web of Science ®Google Scholar
• GonzalezVHCampbellJHolekampNMEarly and long-term responses to anti-vascular endothelial growth factor therapy in diabetic macular edema: analysis of protocol I dataAm J Ophthalmol2016172727927644589
   PubMed Web of Science ®Google Scholar
• Medicine and Healthcare products Regulatory AgencyIluvien® 190 micrograms intravitreal implant in applicator (fluocinolone acetonide) [updated 2015]. Available from http://www.mhra.gov.uk/home/groups/par/documents/websiteresources/con171936.pdfAccessed October 23, 2016
   Google Scholar
• ICE guidelines [TA301]; 2013 [online] Available from: https://www.nice.org.uk/guidance/TA301/chapter/1-GuidanceAccessed October 23, 2016
   Google Scholar
• ApteRSWhat is chronic or persistent diabetic macular edema and how should it be treated?JAMA Ophthalmol2016134328528626746003
   PubMed Web of Science ®Google Scholar
• NauckMKarakiulakisGPerruchoudAPPapakonstantinouERothMCorticosteroids inhibit the expression of the vascular endothelial growth factor gene in human vascular smooth muscle cellsEur J Pharmacol19983412–33093159543253
   PubMed Web of Science ®Google Scholar
• KernTSContributions of inflammatory processes to the development of the early stages of diabetic retinopathyExp Diabetes Res200720079510318274606
   PubMed Web of Science ®Google Scholar
• TamuraHMiyamotoKKiryuJIntravitreal injection of corticosteroid attenuates leukostasis and vascular leakage in experimental diabetic retinaInvest Ophthalmol Vis Sci20054641440144415790913
   PubMed Web of Science ®Google Scholar
• AmoakuWMSakerSStewartEAA review of therapies for diabetic macular oedema and rationale for combination therapyEye (Lond)20152991115113026113500
   PubMed Web of Science ®Google Scholar
• FelinskiEAAntonettiDAGlucocorticoid regulation of endothelial cell tight junction gene expression: novel treatments for diabetic retinopathyCurr Eye Res2005301194995716282129
   PubMed Web of Science ®Google Scholar
• AntonettiDAWolpertEBDeMaioLHarhajNSScadutoRCJrHydrocortisone decreases retinal endothelial cell water and solute flux coincident with increased content and decreased phosphorylation of occludingJ Neurochem200280466767711841574
   PubMed Web of Science ®Google Scholar
• PubChem [database on the Internet]Compound Summary for CID 6215Bethesda, MDNational Center for Biotechnology Information, US Library of Medicine Available from: https://pubchem.ncbi.nlm.nih.gov/compound/fluocinolone_acetonide#section=TopAccessed December 2, 2016
   Google Scholar
• ILUVIENSummary of Product Characteristics Available from: https://www.medicines.org.uk/emc/medicine/27636Accessed October 30, 2016
   Google Scholar
• KaneFEGreenKEOcular pharmacokinetics of fluocinolone acetonide following Iluvien implantation in the vitreous humor of rabbitsJ Ocul Pharmacol Ther2015311111625562126
   PubMed Web of Science ®Google Scholar
• YangYBaileyCHolzFGFAME study groupLong-term outcomes of phakic patients with diabetic macular oedema treated with intravitreal fluocinolone acetonide (FAc) implantsEye (Lond)20152991173118026113503
   PubMed Web of Science ®Google Scholar
• Cunha-VazJAshtonPIezziRFAME Study GroupSustained delivery fluocinolone acetonide vitreous implants: long-term benefit in patients with chronic diabetic macular edemaOphthalmology2014121101892190324935282
   PubMed Web of Science ®Google Scholar
• GoñiFJStalmansIDenisPElevated intraocular pressure after intravitreal steroid injection in diabetic macular edema: monitoring and managementOphthalmol Ther201651476127164896
   PubMedGoogle Scholar
• ParrishRKCampochiaroPAPearsonPAGreenKTraversoCEFAME Study GroupCharacterization of intraocular pressure increases and management strategies following treatment with fluocinolone acetonide intravitreal implants in the FAME trialsOphthalmic Surg Lasers Imaging Retina201647542643527183546
   PubMed Web of Science ®Google Scholar
• ParrishRKTraversoCEGreenKDabisRPFAME Study GroupQuantitative assessment of optic nerve changes in patients with diabetic macular edema treated with fluocinolone acetonide vitreous implantsOphthalmic Surg Lasers Imaging Retina201647541842527183545
   PubMed Web of Science ®Google Scholar
• JonasJBGründlerAECorrelation between mean visual field loss and morphometric optic disk variables in the open-angle glaucomasAm J Ophthalmol199712444884979323939
   PubMed Web of Science ®Google Scholar
• MassinPErginayADupasBCouturierATadayoniREfficacy and safety of sustained-delivery fluocinolone acetonide intravitreal implant in patients with chronic diabetic macular edema insufficiently responsive to available therapies: a real-life studyClin Ophthalmol2016101257126427468222
   PubMed Web of Science ®Google Scholar
• Schmit-EilenbergerVKA novel intravitreal fluocinolone acetonide implant (ILUVIEN®) in the treatment of patients with chronic diabetic macular edema that is insufficiently responsive to other medical treatment options: a case seriesClin Ophthalmol2015980181125999689
   PubMed Web of Science ®Google Scholar
• ElaraoudIAndreattaWKidessAUse of flucinolone acetonide for patients with diabetic macular oedema: patient selection criteria and early outcomes in real-world settingBMC Ophthalmol201616326728265
   PubMed Web of Science ®Google Scholar
• ElaraoudIQuhillHQuhillFCase series investigating the efficacy and safety of bilateral fluocinolone acetonide (ILUVIEN) in patients with diabetic macular edema: 10 eyes with 12 months follow-upOphthalmol Ther20165110510927116231
   PubMed Web of Science ®Google Scholar
• ElaraoudIAttawanAQuhillFCase series investigating the efficacy and safety of bilateral fluocinolone acetonide (ILUVIEN) in patients with diabetic macular edemaOphthalmol Ther2016519510426885863
   PubMed Web of Science ®Google Scholar
• BertelmannTSchulzeSLong-term follow-up of patient with diabetic macular edema receiving fluocinolone acetonide intravitreal implantOphthalmol Ther201541515825672501
   PubMedGoogle Scholar
• Chang-LinJEBurkeJAPengQPharmacokinetics of a sustained-release dexamethasone intravitreal implant in vitrectomized and nonvitrectomized eyesInvest Ophthalmol Vis Sci20115274605460921421864
   PubMed Web of Science ®Google Scholar
• LeeSSGhosnCYuZVitreous VEGF clearance is increased after vitrectomyInvest Ophthalmol Vis Sci20105142135213820019364
   PubMed Web of Science ®Google Scholar
• BoyerDSFaberDGuptaSOzurdex CHAMPLAIN Study GroupDexamethasone intravitreal implant for treatment of diabetic macular edema in vitrectomized patientsRetina201131591592321487341
   PubMed Web of Science ®Google Scholar
• KumarAAlfahadQMitraAElsherbinySLipPLIntravitreal fluocinolone acetonide (ILUVIEN) for treatment of refractory diabetic macular oedema in vitrectomised eyesEye (Lond)201630577027170504
   PubMed Web of Science ®Google Scholar
• QuhillHQuhillFReal-life ILUVIEN (Fluocinolone Acetonide) case study: rapid drying of the macula and improved vision within 2 years after therapy InitiationCase Rep Ophthalmol20167330130728203186
   PubMedGoogle Scholar
• BreusegemCVandewalleEVan CalsterJStalmansIZeyenTPredictive value of a topical dexamethasone provocative test before intravitreal triamcinolone acetonide injectionInvest Ophthalmol Vis Sci200950257357618824737
   PubMed Web of Science ®Google Scholar
• GastonHAbsolonMJThurtleOASattarMASteroid responsiveness in connective tissue diseasesBr J Ophthalmol19836774874906860617
   PubMed Web of Science ®Google Scholar
• PodosSMBeckerBMortonWRHigh myopia and primary open-angle glaucomaAm J Ophthalmol1966626103810435957877
   PubMed Web of Science ®Google Scholar
• MoisseievEMorseLSFluocinolone acetonide intravitreal implant in the visual axisJAMA Ophthalmol201613491067106827367921
   PubMed Web of Science ®Google Scholar
• PapastavrouVTZambarakjiHDooleyIEleftheriadisHJacksonTLObservation: fluocinolone acetonide (ILUVIEN) implant migration into the anterior chamberRetin Cases Brief Rep2017111444626909535
   PubMedGoogle Scholar
• El-GhrablyIASaadADinahCA novel technique for repositioning of a migrated ILUVIEN (Fluocinolone Acetonide) implant into the anterior chamberOphthalmol Ther20154212913326199036
   PubMedGoogle Scholar
• TaylorSChakravarthyUBaileyCon behalf of the ILUVIEN Registry Safety Study (IRISS) Investigators GroupChanges in intraocular pressure after ILUVIEN (190μg fluocinolone acetonide) – real-world experiences following usage in three European countriesPresented at the Royal College of Ophthalmologists Annual CongressMay 2016
   Google Scholar
• BaileyCChakravarthyULoteryAMenonGJohnstonRTalksJUK multi-centre retrospective audit of electronic patient records to assess the real world intraocular pressure events following treatment with ILUVIEN 190 μg intravitreal implant for 24 monthsPoster presentation at the Royal College of Ophthalmologists Annual CongressMay 2016
   Google Scholar
• HenriquesJFigueiraJAmaroMRosasVStructural and functional outcomes of lens status in patients with chronic diabetic macular edema treated with the ILUVIEN implant (0.2 μg/day fluocinolone acetonide): results from the RESPOND trialPresented at: EURETINA CongressSeptember 15; 2015Nice, France
   Google Scholar